BRAF and colorectal cancer: In light of the aforementioned evidence and other findings that patients with BRAF-mutant and/or CIMP-positive colorectal cancer (particularly without MSI or impaired mismatch repair) exhibit worse clinical outcomes [7, 10, 18], this subtype should be regarded as distinct from other molecular subtypes of colorectal cancer and should be treated using different strategies.